During and after treatment
Severe sensitivity reactions can occur following administration of DAT. It is important to closely monitor the patient for adverse events. Further information regarding treatment of anaphylaxis can be found on the following link:
https://www.who.int/publications/i/item/9789240028704

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Clinical description</th>
<th>Action</th>
</tr>
</thead>
</table>
| **Anaphylaxis**          | **Airway:** bronchospasm (hoarse voice, cough, wheeze), obstruction (stridor), dyspnoea, respiratory failure. **Cardiovascular:** hypotension, arrhythmias, rapid weak pulse, angioedema. Any decrease in consciousness level consider anaphylaxis. | Stop infusion immediately  
Call for help  
Administer epinephrine (adrenaline) 1:1000 by intramuscular (IM) injection.  
Dose = 0.01 mg/kg of body weight up to a maximum dose of 0.5 mg  
Repeat dose after 5 minutes for a maximum of TWO further doses if no improvement. Move the patient to a critical care area for continued management.  
Repeat vital signs every 5 minutes |
| **Hypersensitivity reaction** | **Skin:** pruritus, flushing, urticaria (in absence of signs of anaphylaxis)  
Mild increase in temperature  
Mild tachypnoea | Stop the infusion, administer supportive treatment and inform the medical team.  
Repeat vital signs every 5 minutes, if symptoms remain mild, continue the infusion but slow the rate by 50%. |
| **Serum sickness**       | **Fever**  
Maculopapular rash, or urticaria in milder forms  
Arthritis, arthralgia and lymphadenopathy  
Rare: angioedema, glomerulonephritis, Guillain-Barré syndrome, peripheral neuritis or myocarditis | Mild cases of serum sickness frequently resolve spontaneously over a few days to 2 weeks.  
Antihistamines, non-steroidal anti-inflammatory drugs and corticosteroids may be helpful |

REPORTING OF ADVERSE EVENTS IN PHARMACOVIGILANCE PROGRAMMES
Report all adverse events through local or national reporting systems and to the WHO programme for International Drug Monitoring: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/networks/pidm

Remember the FIVE RIGHTS of drug administration:

© World Health Organization 2024. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence. WHO/Diph/DAT/Poster_C/2024.1